A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents

Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity

(2011) Victor A. Gault et al.   CLINICAL SCIENCE

A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo

(2011) Ying Li et al.   PEPTIDES

A GIP Receptor Agonist Exhibits β-Cell Anti-Apoptotic Actions in Rat Models of Diabetes Resulting in Improved β-Cell Function and Glycemic Control

(2010) Scott B. Widenmaier et al.   PLoS One

Therapeutic potential for GIP receptor agonists and antagonists

(2009) Nigel Irwin et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Dorothy Hodgkin Lecture 2008 Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesitydiabetes?

(2008) P. R. Flatt   DIABETIC MEDICINE

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

(2008) P. V. Højberg et al.   DIABETOLOGIA

The islet enhancer vildagliptin: mechanisms of improved glucose metabolism

(2008) B. Ahrén et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

KATPChannel Closure Ameliorates the Impaired Insulinotropic Effect of Glucose-Dependent Insulinotropic Polypeptide in Patients with Type 2 Diabetes

(2008) Kasper Aaboe et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Role of the incretin system in the remission of type 2 diabetes following bariatric surgery

(2008) G. Mingrone   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES